School of Medicine.
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
J Glaucoma. 2021 Mar 1;30(3):276-280. doi: 10.1097/IJG.0000000000001732.
Ahmed and Baerveldt implants succeed in 90.7% of cases for lowering intraocular pressure (IOP) <21 mm Hg at 1 year when used for the treatment of juvenile open-angle glaucoma.
The purpose of this study was to report the 1-year outcomes of Ahmed and Baerveldt tubes as the treatment for juvenile open-angle glaucoma at an academic institution.
Patients 18 to 40 years of age at the time of juvenile open-angle glaucoma diagnosis, who had inadequately controlled glaucoma with an IOP of 18 mm Hg or more on maximum tolerated antiglaucoma therapy that underwent tube shunt surgery with at least 6 months of follow-up were eligible for the study. Exclusion criteria included evidence of neovascular, uveitic or inflammatory, steroid-induced or primary congenital glaucoma, or if they did not have light perception vision. Postoperative failure was defined as an IOP, with or without antiglaucoma drops, >21 mm Hg for 2 consecutive visits after 3 months from surgery, <20% decrease in IOP at 1 year, no light perception, or revision of an implant due to high IOP.
The study population included 32 eyes from 25 patients who underwent tube shunt surgery. The failure rate at 1-year follow-up was 9.3%, and the postoperative complication rate at 1-year follow-up was 9.3%. The average change from baseline to 1 year for IOP was a decrease of 9.8±9.10, for the number of antiglaucoma drops number was a decrease of 0.38±1.06, and for the visual acuity was an increase of 0.03±0.27.
Ahmed and Baerveldt implantation succeeded in lower IOP in 90.7% of patients at 1 year. Continuation of antiglaucoma drops to maintain the IOP after surgery is likely required.
在治疗青少年开角型青光眼时,艾哈迈德和巴伐利特植入物在 1 年内将眼压(IOP)降低至<21mmHg 的成功率为 90.7%。
本研究旨在报告学术机构中艾哈迈德和巴伐利特管作为青少年开角型青光眼治疗方法的 1 年结果。
患有青少年开角型青光眼的患者,年龄在 18 至 40 岁之间,在接受最大耐受抗青光眼治疗后,IOP 仍为 18mmHg 或更高,且有 6 个月以上的随访,有接受管分流手术的指征。排除标准包括新生血管、葡萄膜炎或炎症、类固醇诱导或原发性先天性青光眼的证据,或无光感视力。术后失败定义为手术后 3 个月后连续 2 次就诊时眼压(IOP)>21mmHg,且无需抗青光眼滴注,1 年后 IOP 下降<20%,无光感,或因高眼压而需要更换植入物。
本研究共纳入 25 例 32 只眼接受管分流手术的患者。1 年随访时的失败率为 9.3%,1 年随访时的术后并发症发生率为 9.3%。从基线到 1 年时 IOP 的平均变化为下降 9.8±9.10mmHg,抗青光眼滴注的数量减少 0.38±1.06 滴,视力增加 0.03±0.27。
艾哈迈德和巴伐利特植入物在 1 年内使 90.7%的患者的眼压(IOP)成功降低。术后可能需要继续使用抗青光眼滴注来维持眼压。